Clinical Trial Update: FRAME-001 Personalized Vaccine in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for FRAME-001, a personalized vaccine in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• FRAME-001

Snippet

Sponsor: Frame Pharmaceuticals B.V. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN